Lipella Pharmaceuticals appoints Daniel Cohen to Board and Audit Committee

LIPELLA PHARMACEUTICALS INC.

Board appointed Daniel Cohen as director on March 21, 2023, expanding board to seven members.
Cohen will serve until the next annual meeting and then stand for election.
He was assigned to the Board's audit committee.
No arrangements or understandings with any other persons regarding his appointment.
Entered into no transactions requiring disclosure under Item 404(a).

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Daniel Cohen

Director

LIPO · LIPELLA PHARMACEUTICALS INC.

Effective: 2023-03-21
Filed: March 27, 2023, 7:59 PM ET

On March 21, 2023, the board of directors (the “Board”) of Lipella Pharmaceuticals Inc., a Delaware corporation (the “Company”), pursuant to its powers under the Company’s second amended and restated by-laws, appointed Daniel Cohen as a member of the Board, thereby increasing the Board membership count to seven (7).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Daniel Cohen was appointed as Director at LIPELLA PHARMACEUTICALS INC..

Action: appointed
Role: Director

Exact text from the filing

On March 21, 2023, the board of directors (the “Board”) of Lipella Pharmaceuticals Inc., a Delaware corporation (the “Company”), pursuant to its powers under the Company’s second amended and restated by-laws, appointed Daniel Cohen as a member of the Board, thereby increasing the Board membership count to seven (7).

View on SEC.gov

LIPELLA PHARMACEUTICALS INC. filing history →

Source: SEC EDGAR

accession 0001753926-23-000301

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.